From next month, Servier Korea’s 'Onivyde (irinotecan liposome injection)' will be available with insurance benefits for use in second-line or higher treatment of pancreatic cancer.

However, patients eligible for the insurance benefit are limited to patients with an ECOG(European Cooperative Oncology Group) of 0 to 1.

The Health Insurance Review and Assessment Service recently disclosed the 'Revision of notice according to medicines prescribed or administered to cancer patients' that contain the changes mentioned above and is reviewing opinions until the 26th.

If no objections are made, the agenda will be deliberated and passed by the Ministry of Health and Welfare's H